FDA.reportPublic FDA data

quizartinib 17.7 MG Oral Tablet

RxCUI
2643054
RxNorm name
quizartinib 17.7 MG Oral Tablet
Display name
quizartinib 17.7 MG Oral Tablet
Full name
quizartinib 17.7 MG Oral Tablet
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:38:51

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VANFLYTAQUIZARTINIBDaiichi Sankyo Inc.29cdbcfe-497d-4e78-bb7b-2d4acafe8e862026-04-16Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2643054

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
29cdbcfe-497d-4e78-bb7b-2d4acafe8e86quizartinib 17.7 MG Oral Tablet [PSN] · quizartinib 17.7 MG Oral Tablet [SCD] · quizartinib 17.7 MG (equivalent to 20 MG quizartinib dihydrochloride) Oral Tablet [SY]311These highlights do not include all the information needed to use VANFLYTA safely and effectively. See full prescribing information for VANFLYTA. VANFLYTA ® (quizartinib) tablets, for oral use Initial U.S. Approval: 202320260416